Lista de obras -

Antiviral Therapy of Chronic Hepatitis B

artículo científico publicado en 2014

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues

artículo científico publicado en 2010

Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infection

artículo científico publicado en 2016

Association of HLA-DPA1 and HLA-DPB1 polymorphisms with spontaneous HBsAg seroclearance in Caucasians

scientific article published on 28 January 2019

Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection

artículo científico publicado en 2013

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

artículo científico publicado en 2019

Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C.

artículo científico publicado en 2013

Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)

artículo científico publicado en 2020

Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort

artículo científico publicado en 2018

Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015.

artículo científico publicado en 2016

Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection.

artículo científico publicado en 2012

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

artículo científico publicado en 2004

Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B

scientific article published on 12 September 2020

Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing

scientific article published on 20 December 2019

Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians

artículo científico publicado en 2014

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

article

Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy

artículo científico publicado en 2012

Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients

scientific article published on 11 July 2019

Flares during long-term entecavir therapy in chronic hepatitis B.

artículo científico publicado en 2016

Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B

scientific article published on 08 January 2020

Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss

artículo científico publicado en 2020

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment.

artículo científico publicado en 2018

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

artículo científico publicado en 2010

Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients

artículo científico publicado en 2018

Management of chronic hepatitis B: status and challenges beyond treatment guidelines

scientific article published on 19 October 2010

Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).

artículo científico publicado en 2016

N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury

artículo científico publicado en 2017

Necessity of transnasal gastroscopy in routine diagnostics: a patient-centred requirement analysis

New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.

artículo científico publicado en 2013

Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population

artículo científico publicado en 2018

Prävention der nosokomialen Übertragung von Hepatitis-B-Virus (HBV) und Hepatitis-C-Virus (HCV) durch im Gesundheitswesen Tätige : Empfehlungen der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e. V

scientific article published on 01 February 2020

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers.

artículo científico publicado en 2017

Reactivation of viral replication after replacement of tenofovir by adefovir

artículo científico publicado en 2005

Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H.

artículo científico publicado en 2009

Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections

scientific article published on 01 July 2019

Role of tenofovir in the treatment of chronic HBV infection

article published in 2008

Serum HBV RNA as a Predictor of Peginterferon Alfa-2a (40KD) Response in Patients With HBeAg-Positive Chronic Hepatitis B.

artículo científico publicado en 2018

Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors.

artículo científico publicado en 2014

Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B

artículo científico publicado en 2020

Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.

artículo científico publicado en 2018

Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation

artículo científico publicado en 2003

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

artículo científico publicado en 2006

Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication

artículo científico publicado en 2002

Treatment of HBV related cirrhosis

artículo científico

Lista de obras de

Antiviral Therapy of Chronic Hepatitis B

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues

Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infection

Association of HLA-DPA1 and HLA-DPB1 polymorphisms with spontaneous HBsAg seroclearance in Caucasians

Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C.

Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)

Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort

Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015.

Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection.

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B

Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing

Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy

Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients

Flares during long-term entecavir therapy in chronic hepatitis B.

Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B

Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment.

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients

Management of chronic hepatitis B: status and challenges beyond treatment guidelines

Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).

N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury

Necessity of transnasal gastroscopy in routine diagnostics: a patient-centred requirement analysis

New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.

Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population

Prävention der nosokomialen Übertragung von Hepatitis-B-Virus (HBV) und Hepatitis-C-Virus (HCV) durch im Gesundheitswesen Tätige : Empfehlungen der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e. V

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers.

Reactivation of viral replication after replacement of tenofovir by adefovir

Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H.

Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections

Role of tenofovir in the treatment of chronic HBV infection

Serum HBV RNA as a Predictor of Peginterferon Alfa-2a (40KD) Response in Patients With HBeAg-Positive Chronic Hepatitis B.

Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors.

Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B

Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.

Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication

Treatment of HBV related cirrhosis

Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients